Characterization of rare transforming KRAS mutations in sporadic colorectal cancer

Cancer Biology and Therapy

Volumn 15, Issue 6, 2014, Pages 768-776

  Tong, Joanna H M ^a,b,c   Lung, Raymond W M ^a,b,c   Sin, Frankie M C ^a,b,c   Law, Peggy P Y ^a,b,c   Kang, Wei ^a,b,c   Chan, Anthony W H ^a   Ma, Brigette B Y ^b   Mak, Tony W C ^b   Ng, Simon S M ^b,c   To, Ka Fai ^a,b,c  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^c Li Ka Shing Institute of Health Sciences   (Hong Kong)

Author keywords

Colorectal cancer; KRAS; Targeted therapy

Indexed keywords

PHOSPHATE BINDING PROTEIN; RAS PROTEIN; KRAS PROTEIN, HUMAN; ONCOPROTEIN;

3T3 CELL LINE; ADULT; ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL FUNCTION; CODON USAGE; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; FEMALE; GENE INSERTION; GENETIC TRANSFECTION; GENETIC VARIABILITY; HEK293 CELL LINE; HUMAN; HUMAN CELL; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MALIGNANT TRANSFORMATION; MOUSE; MUTATION RATE; NONHUMAN; ONCOGENE K RAS; RECTUM TUMOR; SEX DIFFERENCE; SIGNAL TRANSDUCTION; WILD TYPE; ADENOCARCINOMA; AGED; ANIMAL; BAGG ALBINO MOUSE; CANCER TRANSPLANTATION; COLORECTAL NEOPLASMS; GENETIC ASSOCIATION; GENETICS; INDEL MUTATION; MIDDLE AGED; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; NUDE MOUSE; PATHOLOGY; SEX RATIO; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANIMALS; BASE SEQUENCE; COLORECTAL NEOPLASMS; DNA MUTATIONAL ANALYSIS; FEMALE; GENETIC ASSOCIATION STUDIES; HEK293 CELLS; HUMANS; INDEL MUTATION; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MIDDLE AGED; MUTATION, MISSENSE; NEOPLASM TRANSPLANTATION; NIH 3T3 CELLS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; SEX DISTRIBUTION; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 84901710704     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.28550     Document Type: Article

References (44)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61:69-90; PMID:21296855; http://dx.doi.org/ 10.3322/caac.20107
2. Markman B, Javier Ramos F, Capdevila J, Tabernero J. EGFR and KRAS in colorectal cancer. Adv Clin Chem 2010; 51:71-119; PMID:20857619; http://dx.doi.org/10.1016/S0065-2423(10)51004-7
3. Brand TM, Wheeler DL. KRAS mutant colorectal tumors: past and present. Small GTPases 2012; 3:34-9; PMID:22714415; http://dx.doi.org/10.4161/sgtp.18751
4. Benvenuti S, Sartore-Bianchi A, Di Nicolantonio F, Zanon C, Moroni M, Veronese S, Siena S, Bardelli A. Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies. Cancer Res 2007; 67:2643-8; PMID:17363584; http://dx.doi.org/10.1158/0008-5472.CAN-06-4158
5. Lièvre A, Bachet JB, Boige V, Cayre A, Le Corre D, Buc E, Ychou M, Bouché O, Landi B, Louvet C, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008; 26:374-9; PMID:18202412; http://dx.doi.org/10. 1200/JCO.2007.12.5906
6. Jimeno A, Messersmith WA, Hirsch FR, Franklin WA, Eckhardt SG. KRAS mutations and sensitivity to epidermal growth factor receptor inhibitors in colorectal cancer: practical application of patient selection. J Clin Oncol 2009; 27:1130-6; PMID:19124802; http://dx.doi.org/10.1200/JCO.2008.19.8168
7. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008; 26:1626-34; PMID:18316791; http://dx.doi.org/10.1200/JCO.2007.14.7116
8. Bollag G, Adler F, elMasry N, McCabe PC, Conner E Jr., Thompson P, McCormick F, Shannon K. Biochemical characterization of a novel KRAS insertion mutation from a human leukemia. J Biol Chem 1996; 271:32491-4; PMID:8955068; http://dx.doi.org/10.1074/jbc.271.51.32491
9. Tejpar S, Celik I, Schlichting M, Sartorius U, Bokemeyer C, Van Cutsem E. Association of KRAS G13D tumor mutations with outcome in patients with metastatic colorectal cancer treated with firstline chemotherapy with or without cetuximab. J Clin Oncol 2012; 30:3570-7; PMID:22734028; http://dx.doi.org/10. 1200/JCO.2012.42.2592
10. Edkins S, O'Meara S, Parker A, Stevens C, Reis M, Jones S, Greenman C, Davies H, Dalgliesh G, Forbes S, et al. Recurrent KRAS codon 146 mutations in human colorectal cancer. Cancer Biol Ther 2006; 5:928-32; PMID:16969076; http://dx.doi.org/10.4161/cbt.5.8.3251
11. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA. Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study. J Natl Cancer Inst 1998; 90:675-84; PMID:9586664; http://dx.doi.org/10. 1093/jnci/90.9.675
12. Zulhabri O, Rahman J, Ismail S, Isa MR, Wan Zurinah WN. Predominance of G to A codon 12 mutation K-ras gene in Dukes' B colorectal cancer. Singapore Med J 2012; 53:26-31; PMID:22252179
13. Russo A, Bazan V, Agnese V, Rodolico V, Gebbia N. Prognostic and predictive factors in colorectal cancer: Kirsten Ras in CRC (RASCAL) and TP53CRC collaborative studies. Ann Oncol 2005; 16(Suppl 4):iv44-9; PMID:15923428; http://dx.doi.org/10.1093/annonc/mdi907
14. Richman SD, Seymour MT, Chambers P, Elliott F, Daly CL, Meade AM, Taylor G, Barrett JH, Quirke P. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27:5931-7; PMID:19884549; http://dx.doi.org/10.1200/JCO.2009.22.4295
15. Kim ST, Park KH, Kim JS, Shin SW, Kim YH. Impact of KRAS Mutation Status on Outcomes in Metastatic Colon Cancer Patients without Anti-Epidermal Growth Factor Receptor Therapy. Cancer Res Treat 2013; 45:55-62; PMID:23613671; http://dx.doi.org/10.4143/crt.2013.45.1.55
16. Petrelli F, Coinu A, Cabiddu M, Ghilardi M, Barni S. KRAS as prognostic biomarker in metastatic colorectal cancer patients treated with bevacizumab: a pooled analysis of 12 published trials. Med Oncol 2013; 30:650; PMID:23828442; http://dx.doi.org/10.1007/s12032-013-0650-4
17. Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T, Saijo N, Ohashi Y, Sugihara K. KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol 2013; 43:706-12; PMID:23657052; http://dx.doi.org/10. 1093/jjco/hyt062
18. Adelstein BA, Dobbins TA, Harris CA, Marschner IC, Ward RL. A systematic review and meta-analysis of KRAS status as the determinant of response to anti-EGFR antibodies and the impact of partner chemotherapy in metastatic colorectal cancer. Eur J Cancer 2011; 47:1343-54; PMID:21550229; http://dx.doi.org/10.1016/j.ejca.2011.03.031
19. Mao C, Zhou J, Yang Z, Huang Y, Wu X, Shen H, Tang J, Chen Q. KRAS, BRAF and PIK3CA mutations and the loss of PTEN expression in Chinese patients with colorectal cancer. PLoS One 2012; 7:e36653; PMID:22586484; http://dx.doi.org/10. 1371/journal.pone.0036653
20. Yunxia Z, Jun C, Guanshan Z, Yachao L, Xueke Z, Jin L. Mutations in epidermal growth factor receptor and K-ras in Chinese patients with colorectal cancer. BMC Med Genet 2010; 11:34; PMID:20184776; http://dx.doi.org/10.1186/ 1471-2350-11-34
21. Samowitz WS, Curtin K, Schaffer D, Robertson M, Leppert M, Slattery ML. Relationship of Ki-ras mutations in colon cancers to tumor location, stage, and survival: a population-based study. Cancer Epidemiol Biomarkers Prev 2000; 9:1193-7; PMID:11097226
22. Elnatan J, Goh HS, Smith DR. C-KI-RAS activation and the biological behaviour of proximal and distal colonic adenocarcinomas. Eur J Cancer 1996; 32A:491-7; PMID:8814697; http://dx.doi.org/10.1016/0959-8049(95)00567-6
23. Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, et al. Colorectal carcinomas with KRAS mutation are associated with distinctive morphological and molecular features. Mod Pathol 2013; 26:825-34; PMID:23348904; http://dx.doi.org/10.1038/modpathol. 2012.240
24. Lin JK, Chang SC, Wang HS, Yang SH, Jiang JK, Chen WC, Lin TC, Li AF. Distinctive clinicopathological features of Ki-ras mutated colorectal cancers. J Surg Oncol 2006; 94:234-41; PMID:16900509; http://dx.doi.org/10.1002/jso.20438
25. Pai RK, Jayachandran P, Koong AC, Chang DT, Kwok S, Ma L, Arber DA, Balise RR, Tubbs RR, Shadrach B, et al. BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic features. Am J Surg Pathol 2012; 36:744-52; PMID:22314188; http://dx.doi.org/10.1097/PAS. 0b013e31824430d7
26. Benedix F, Kube R, Meyer F, Schmidt U, Gastinger I, Lippert H; Colon/Rectum Carcinomas (Primary Tumor) Study Group. Comparison of 17,641 patients with right- and left-sided colon cancer: differences in epidemiology, perioperative course, histology, and survival. Dis Colon Rectum 2010; 53:57-64; PMID:20010352; http://dx.doi.org/10.1007/DCR.0b013e3181c703a4
27. Bufill JA. Colorectal cancer: evidence for distinct genetic categories based on proximal or distal tumor location. Ann Intern Med 1990; 113:779-88; PMID:2240880; http://dx.doi.org/10.7326/0003-4819-113-10-779
28. Sugai T, Habano W, Jiao YF, Tsukahara M, Takeda Y, Otsuka K, Nakamura S. Analysis of molecular alterations in left- and right-sided colorectal carcinomas reveals distinct pathways of carcinogenesis: proposal for new molecular profile of colorectal carcinomas. J Mol Diagn 2006; 8:193-201; PMID:16645205; http://dx.doi.org/10.2353/jmoldx.2006.050052
29. Soong R, Powell B, Elsaleh H, Gnanasampanthan G, Smith DR, Goh HS, Joseph D, Iacopetta B. Prognostic significance of TP53 gene mutation in 995 cases of colorectal carcinoma. Influence of tumour site, stage, adjuvant chemotherapy and type of mutation. Eur J Cancer 2000; 36:2053-60; PMID:11044641; http:// dx.doi.org/10.1016/S0959-8049(00)00285-9
30. Iacopetta B. Are there two sides to colorectal cancer? Int J Cancer 2002; 101:403-8; PMID:12216066; http://dx.doi.org/10.1002/ijc.10635
31. Brink M, de Goeij AF, Weijenberg MP, Roemen GM, Lentjes MH, Pachen MM, Smits KM, de Bruïne AP, Goldbohm RA, van den Brandt PA. K-ras oncogene mutations in sporadic colorectal cancer in The Netherlands Cohort Study. Carcinogenesis 2003; 24:703-10; PMID:12727799; http://dx.doi.org/10.1093/carcin/ bgg009
32. Reimann C, Arola M, Bierings M, Karow A, van den Heuvel-Eibrink MM, Hasle H, Niemeyer CM, Kratz CP. A novel somatic K-Ras mutation in juvenile myelomonocytic leukemia. Leukemia 2006; 20:1637-8; PMID:16826224; http://dx.doi.org/10.1038/sj.leu.2404303
33. Tartaglia M, Martinelli S, Cazzaniga G, Cordeddu V, Iavarone I, Spinelli M, Palmi C, Carta C, Pession A, Aricò M, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004; 104:307-13; PMID:14982869; http://dx.doi.org/10.1182/blood-2003-11-3876
34. Servomaa K, Kiuru A, Kosma VM, Hirvikoski P, Rytömaa T. p53 and K-ras gene mutations in carcinoma of the rectum among Finnish women. Mol Pathol 2000; 53:24-30; PMID:10884918; http://dx.doi.org/10.1136/mp.53.1.24
35. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009; 15:4554-60; PMID:19584155; http://dx.doi.org/10.1158/1078-0432.CCR-09-0089
36. Wójcik P, Kulig J, Okoń K, Zazula M, Moździoch I, Niepsuj A, Stachura J. KRAS mutation profile in colorectal carcinoma and novel mutation - internal tandem duplication in KRAS. Pol J Pathol 2008; 59:93-6; PMID:18669174
37. Khosravi-Far R, White MA, Westwick JK, Solski PA, Chrzanowska-Wodnicka M, Van Aelst L, Wigler MH, Der CJ. Oncogenic Ras activation of Raf/mitogen-activated protein kinase-independent pathways is sufficient to cause tumorigenic transformation. Mol Cell Biol 1996; 16:3923-33; PMID:8668210
38. Tong JH, Ng DC, Chau SL, So KK, Leung PP, Lee TL, Lung RW, Chan MW, Chan AW, Lo KW, et al. Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma. BMC Cancer 2010; 10:253; PMID:20525238; http://dx.doi.org/10.1186/1471-2407-10-253
39. Lung RW, Tong JH, Sung YM, Leung PS, Ng DC, Chau SL, Chan AW, Ng EK, Lo KW, To KF. Modulation of LMP2A expression by a newly identified Epstein-Barr virus-encoded microRNA miR-BART22. Neoplasia 2009; 11:1174-84; PMID:19881953
40. Kang W, Tong JH, Chan AW, Lee TL, Lung RW, Leung PP, So KK, Wu K, Fan D, Yu J, et al. Yesassociated protein 1 exhibits oncogenic property in gastric cancer and its nuclear accumulation associates with poor prognosis. Clin Cancer Res 2011; 17:2130-9; PMID:21346147; http://dx.doi.org/10.1158/1078-0432.CCR-10- 2467
41. Imamura Y, Morikawa T, Liao X, Lochhead P, Kuchiba A, Yamauchi M, Qian ZR, Nishihara R, Meyerhardt JA, Haigis KM, et al. Specific mutations in KRAS codons 12 and 13, and patient prognosis in 1075 BRAF wild-type colorectal cancers. Clin Cancer Res 2012; 18:4753-63; PMID:22753589; http://dx.doi.org/10. 1158/1078-0432.CCR-11-3210
42. De Roock W, Claes B, Bernasconi D, De Schutter J, Biesmans B, Fountzilas G, Kalogeras KT, Kotoula V, Papamichael D, Laurent-Puig P, et al. Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis. Lancet Oncol 2010; 11:753-62; PMID:20619739; http://dx.doi.org/10.1016/S1470-2045(10)70130-3
43. Chang YS, Yeh KT, Chang TJ, Chai C, Lu HC, Hsu NC, Chang JG. Fast simultaneous detection of K-RAS mutations in colorectal cancer. BMC Cancer 2009; 9:179; PMID:19515263; http://dx.doi.org/10.1186/1471-2407-9-179
44. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359:1757-65; PMID:18946061; http://dx.doi.org/10.1056/NEJMoa0804385